Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 43
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Acta Pol Pharm ; 59(1): 25-9, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12026108

RESUMO

Talampicillin stability in aqueous solutions was studied in a broad range of pH values using as medium solutions of hydrochloric acid (pH 0.4-1.8), phosphate buffers (pH 2.05-3.13 and 6.03-8.04), acetate buffer (pH 3.87-5.28) and borate buffer (pH 8.90-9.10) as well as sodium hydroxide solution (pH 11.48). For the determination of talampicillin concentration changes in kinetic studies, two methods were used: iodometric and spectrophotometric in UV (lambda(max) = 254.5 nm). The catalytic velocity constants (k(H+), k(x), k(o)) were established, the log k-pH profile (35 degrees C) was found, thermodynamic parameters were calculated of the hydrolysis reaction of the beta-lactam bond (k(H+): E(A)= 67.9 kJ mol(-1), delta S = -92.4 J K(-1) mol(-1), delta G = 92.6 kJ mol(-1); k(x): E(A) = 31.8 kJ mol(-1), delta S = -347.1 J K(-1) mol(-1), delta G = 131.1 kJ mol(-1); k(o), pH = 5.28: E(A) = 98.0 kJ mol(-1), delta S = -50.3 J K(-1) mol(-1), delta G = 110.3 kJ mol(-1) at 20 degrees C), and the stability of the lactone bond was studied in the medium with the highest stability of beta-lactam bond of talampicillin (pH 5.28: k(o): E(A)= 32.5 kJ mol(-1), delta S = -220.5 J K(-1) mol(-1), delta G = 94.7 kJ mol(-1) in 20 degrees C), at controlled ionic strength (mu = 0.5 mol l(-1)).


Assuntos
Penicilinas/farmacocinética , Talampicilina/farmacocinética , Antibacterianos/farmacocinética , Hidrólise , Soluções Farmacêuticas/farmacocinética , Termodinâmica
2.
Artigo em Inglês | MEDLINE | ID: mdl-11402275

RESUMO

OBJECTIVE: The purpose of this study was to evaluate various oral antimicrobial agent levels in tooth extraction sites. STUDY DESIGN: The concentration of dental alveolar blood in extraction wounds after the oral administration of talampicillin (500 mg), cefaclor (500 mg), cefteram pivoxil (200 mg), cefuroxime axetil (250 mg), cefdinir (200 mg), and ofloxacin (100 mg) was determined in 338 patients and was assessed on the basis of its antimicrobial activity against Streptococcus isolated in odontogenic infections. RESULTS: The percentage of patients whose concentrations exceeded the minimum inhibitory concentration for 90% of Streptococcus was 62.5% to 100% for talampicillin at 30 to 360 minutes, 0% to 12.5% for cefaclor at 30 to 360 minutes, 18.2% to 100% for cefteram pivoxil at 30 to 480 minutes, 50% to 100% for cefuroxime axetil at 30 to 480 minutes, 0% to 50% for cefdinir at 16 to 290 minutes, and 0% to 40% for ofloxacin at 30 to 480 minutes. CONCLUSION: These results indicate that talampicillin, cefteram pivoxil, and cefuroxime axetil have minimum inhibitory concentration levels for 90% of Streptococcus in tooth sockets.


Assuntos
Antibacterianos/sangue , Cefmenoxima/análogos & derivados , Extração Dentária , Administração Oral , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Processo Alveolar/metabolismo , Antibacterianos/uso terapêutico , Cefaclor/sangue , Cefaclor/uso terapêutico , Cefdinir , Cefmenoxima/sangue , Cefmenoxima/uso terapêutico , Cefuroxima/análogos & derivados , Cefuroxima/sangue , Cefuroxima/uso terapêutico , Cefalosporinas/sangue , Cefalosporinas/uso terapêutico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ofloxacino/sangue , Ofloxacino/uso terapêutico , Penicilinas/sangue , Penicilinas/uso terapêutico , Pró-Fármacos/análise , Pró-Fármacos/uso terapêutico , Infecções Estafilocócicas/tratamento farmacológico , Streptococcus/efeitos dos fármacos , Talampicilina/sangue , Talampicilina/uso terapêutico , Fatores de Tempo , Doenças Dentárias/tratamento farmacológico , Doenças Dentárias/microbiologia , Alvéolo Dental/metabolismo
4.
Am J Vet Res ; 57(7): 1021-4, 1996 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8807014

RESUMO

OBJECTIVES: To determine the oral bioavailabilities of 3 ampicillin esters (pivampicillin, bacampicillin, and talampicillin) and ampicillin sodium, and to determine in vitro stability of the ampicillin esters in ileal contents (pH 8.3 to 8.5). DESIGN: A crossover design to administer the 4 drugs orally, and ampicillin i.v. to all horses in the study. ANIMALS: 4 healthy adult horses. PROCEDURE: The drugs were administered intragastrically to the horses at a dosage equimolar to 15 mg of ampicillin/kg of body weight. Also, ampicillin sodium was administered i.v. at the same dosage. Blood samples were taken up to 12 hours after drug administration, and ampicillin concentrations in plasma were determined. For the in vitro study, the ampicillin esters were incubated at 37 C in ileal contents obtained from ponies with cecal fistulas. After incubation, the remaining intact ester and the formed ampicillin were measured. RESULTS: Absolute oral bioavailability was 31, 39, 23, and 2% for pivampicillin, bacampicillin, talampicillin, and ampicillin sodium, respectively. In the in vitro study, 90% decomposition of the ester took place in 30, 60, and 5 minutes, for pivampicillin, bacampicillin, and talampicillin, respectively. CONCLUSIONS: Pivampicillin and bacampicillin are promising candidates for oral antibiotic treatment of horses. The rapid decomposition of ampicillin esters is caused by chemical hydrolysis at the high pH of equine ileal contents.


Assuntos
Ampicilina/análogos & derivados , Ampicilina/farmacocinética , Penicilinas/farmacocinética , Pivampicilina/farmacocinética , Talampicilina/farmacocinética , Administração Oral , Ampicilina/administração & dosagem , Ampicilina/química , Animais , Disponibilidade Biológica , Estudos Cross-Over , Estabilidade de Medicamentos , Feminino , Meia-Vida , Cavalos , Absorção Intestinal , Masculino , Taxa de Depuração Metabólica , Orquiectomia , Penicilinas/administração & dosagem , Penicilinas/química , Pivampicilina/administração & dosagem , Pivampicilina/química , Talampicilina/administração & dosagem , Talampicilina/química
5.
J Dermatol ; 18(5): 277-80, 1991 May.
Artigo em Inglês | MEDLINE | ID: mdl-1834713

RESUMO

A review of 872 cases of drug eruption reported in the Japanese dermatological journals from 1984 to 1989 has revealed a growing subset related to treatment with prodrugs, in which the responsible agent may be the metabolite rather than the prodrug itself. This situation is the result of the presence in tissues and fluids of only the metabolite following absorption and degradation of the prodrug. Because of this condition, patients with drug eruptions after prodrug treatment may develop positive patch test and/or lymphocyte stimulation test reactions not only with the introduced prodrug but also with the metabolite produced in vivo and further with other prodrugs which degrade into the same metabolite.


Assuntos
Erupção por Droga/etiologia , Pró-Fármacos/efeitos adversos , Adulto , Ampicilina/efeitos adversos , Ampicilina/análogos & derivados , Reações Cruzadas , Feminino , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Talampicilina/efeitos adversos
6.
Pharm Res ; 5(5): 288-96, 1988 May.
Artigo em Inglês | MEDLINE | ID: mdl-3244638

RESUMO

The utilization time for a parenteral prodrug solution with a bioavailable fraction of unity was defined as the time during which the total of the prodrug concentration and the drug concentration equals or exceeds 90% of the initial prodrug concentration. This utilization time was calculated as a function of pH, buffer, and temperature using the experimentally determined rate expressions for bacampicillin and talampicillin. The results were compared to the shelf life of ampicillin solutions under identical storage conditions. First-order rate constants were determined for conversion of the prodrugs to ampicillin (kc), for beta-lactam degradation of the prodrugs (knc), for the overall loss of prodrugs (ksum), and for beta-lactam degradation of ampicillin (kh) in aqueous solutions at 25.0 to 60.0 degrees C, mu = 0.5, in the pH range 0.90 to 8.4. Loss of bacampicillin proceeded primarily by degradation at pH levels below 4 but was due predominantly to conversion at pH levels above 5. Loss of talampicillin was due primarily to conversion throughout the entire pH range. While the prodrug utilization times were approximately twice the shelf life of ampicillin in acidic solutions, ampicillin was significantly better in neutral solutions. The results illustrate the potential for increased prodrug storage periods when utilization time is defined on the basis of the bioactivity rather than on the prodrug concentration alone.


Assuntos
Ampicilina/análogos & derivados , Pró-Fármacos , Talampicilina/análise , Ampicilina/análise , Fenômenos Químicos , Físico-Química , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Concentração de Íons de Hidrogênio , Hidrólise , Infusões Intravenosas , Cinética , Soluções
7.
Antimicrob Agents Chemother ; 32(4): 566-7, 1988 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-3377465

RESUMO

Ampicillin concentrations in human serum and dental granulomas of 31 patients were determined after a single oral dose of talampicillin (equivalent to 500 mg of ampicillin) was administered to each. The specimens were taken at 1.5, 2.0, 2.5, 3.0, and 3.5 h after the administration of talampicillin. The mean peak ampicillin concentrations in serum and dental granulomas occurred at identical times, 2.5 h, and were 8.29 micrograms/ml (range, 1.81 to 13.20 micrograms/ml) and 2.94 micrograms/g (range, 1.14 to 7.16 micrograms/g), respectively. The mean dental granuloma/serum ampicillin concentration ratio at the peak time (2.5 h) was 0.42 (range, 0.29 to 0.56). Ampicillin concentrations in dental granulomas exceeded most of the MICs for the bacteria commonly isolated from odontogenic infection.


Assuntos
Ampicilina/análogos & derivados , Ampicilina/metabolismo , Granuloma Periapical/metabolismo , Talampicilina/metabolismo , Administração Oral , Adulto , Ampicilina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
8.
Int J Clin Pharmacol Res ; 8(4): 263-6, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-3182115

RESUMO

There are references in the literature describing the influence of bronchial inflammation on the antibiotic concentration in bronchial secretions, including netilmicin concentrations in the bronchial secretion of patients undergoing tracheotomy. Three semi-synthetic penicillins are compared--bacampicillin, amoxicillin and talampicillin--administered frequently in the treatment of various respiratory infections. The three antibiotics were administered successively for two days each, in the same patient, irrespective of other drugs. At the same time the cytologic evaluation of the degree of bronchial inflammation was done. The antibiotic concentrations in bronchial secretions and in sera were measured at the same time. The results showed that the concentration of antibiotics in bronchial secretions of patients undergoing tracheotomy was proportional to the degree of bronchial inflammation. Among the semi-synthetic penicillins investigated the highest degree of concentration in the bronchial secretion was obtained after the bacampicillin.


Assuntos
Amoxicilina/análise , Ampicilina/análogos & derivados , Brônquios/metabolismo , Talampicilina/análise , Amoxicilina/administração & dosagem , Amoxicilina/uso terapêutico , Ampicilina/administração & dosagem , Ampicilina/análise , Ampicilina/uso terapêutico , Brônquios/análise , Bronquite/tratamento farmacológico , Humanos , Talampicilina/administração & dosagem , Talampicilina/uso terapêutico , Fatores de Tempo
9.
Gen Pharmacol ; 19(4): 515-6, 1988.
Artigo em Inglês | MEDLINE | ID: mdl-3410274

RESUMO

1. Ampicillin concentrations in human serum and periodontal membrane after a single oral administration of talampicillin (500 mg) were assayed by the agar diffusion (paper disc) method. 2. The peak times of serum and periodontal membrane were identical, being 150 min after administration. 3. The peak concentrations of serum and periodontal membrane were 7.81 micrograms/ml and 4.11 micrograms/g, respectively. 4. The mean ratio of periodontal membrane to serum concentration at the peak time was 0.53.


Assuntos
Ampicilina/análogos & derivados , Ampicilina/sangue , Periodonto/metabolismo , Talampicilina/farmacocinética , Administração Oral , Humanos , Membranas/metabolismo , Talampicilina/administração & dosagem
11.
J Pharm Pharmacol ; 39(1): 5-8, 1987 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-2880985

RESUMO

A high-performance liquid chromatographic method has been developed for the determination of ampicillin (I) and its metabolites [5R,6R)-penicilloate (II), the (5S,6R)-epimer (III), and piperazine-2,5-dione (IV)) in human urine. The assay was based on the measurement of the absorbance at 300 nm following the postcolumn alkaline degradation with 0.75 M sodium hydroxide, 2 X 10(-3) M mercuric chloride, and 1 X 10(-2) M ethylenediaminetetraacetic acid disodium salt in solution. The limits of accurate determination were 0.5 microgram mL-1 for I, 2.0 microgram mL-1 for II and III, and 1.0 microgram mL-1 for IV in neat urine samples with a 10 microL injection. At concentrations of compounds I-IV of 5 micrograms mL-1, within- and between-run precisions were 1.10-4.03% and 0.93-2.34%, respectively. The urinary levels of I and its metabolites were quantified by the proposed method.


Assuntos
Ampicilina/urina , Biotransformação , Cromatografia Líquida de Alta Pressão , Ácido Edético , Humanos , Cloreto de Mercúrio , Hidróxido de Sódio , Talampicilina/metabolismo
12.
Tokai J Exp Clin Med ; 11(2): 91-9, 1986 May.
Artigo em Inglês | MEDLINE | ID: mdl-3564081

RESUMO

Parameters for blood concentrations of the peroral antibiotics talampicil in and bacampicillin, in NZW rabbits were determined using a two compartment model. On the basis of these pharmacokinetic parameters, a three compartment model was prepared for the concentrations of these drugs in the tongue, gingiva, submandibular gland, parotid gland, cervical lymph-node and mandibular bone. Simulation curves based on the parameters of tissue concentrations revealed visual conformity to the measured values.


Assuntos
Ampicilina/análogos & derivados , Talampicilina/metabolismo , Ampicilina/sangue , Ampicilina/metabolismo , Animais , Cinética , Coelhos , Talampicilina/sangue , Distribuição Tecidual
13.
Scand J Infect Dis Suppl ; 49: 73-84, 1986.
Artigo em Inglês | MEDLINE | ID: mdl-3547627

RESUMO

The ampicillin prodrugs bacampicillin, pivampicillin, and talampicillin, the mecillinam prodrug pivmecillinam and the sulbactam prodrug sulbactam pivoxil all have a greatly improved oral availability compared to the parent drug. They show no antibacterial activity themselves until transformed into active drugs after absorption. This double advantage makes them less likely to influence the intestinal microbial ecosystem. Ampicillin has been reported to cause marked changes in the colon microflora, particularly as regards Enterobacter species, Klebsiella species, enterococci, lactobacilli, bacteroides, and clostridia, in contrast to pivampicillin, which did not exert much influence. Similarly, talampicillin has been reported to have less influence than ampicillin on the colon flora. Diarrhoea was more common after ampicillin and was accompanied by an overgrowth of Candida. Pivmecillinam has been reported to reduce the number of Escherichia coli and lactobacilli. No changes were seen in the colon flora of subjects receiving bacampicillin tablets. This was verified in a parallel group study, in which one group was given the combination of bacampicillin and sulbactam pivoxil, the other bacampicillin, for seven days. Of the subjects given the combination, five had a moderate and ten a considerable change in their colon microflora. The subjects were often heavily colonized by new aerobic strains such as enterococci, E. coli, Bacillus, Enterobacter, Aeromonas, and yeasts. Among the anaerobes, Veillonella, the bifidobacteria-lactobacillus group, and bacteroides decreased. Some strains of clostridia decreased but there was also a colonization with new strains. One subject was colonized with Clostridium difficile. Diarrhoea was seen only during the week of active drug administration in the group given the combination. The symptoms generally appeared on the second or third day of treatment and had, in most cases, subsided at the end of treatment. The results illustrate the correlation between disturbances in the intestinal microbial ecosystem and intestinal adverse reactions.


Assuntos
Ampicilina/análogos & derivados , Antibacterianos/farmacologia , Bactérias/efeitos dos fármacos , Intestinos/microbiologia , Administração Oral , Ampicilina/administração & dosagem , Ampicilina/metabolismo , Ampicilina/farmacologia , Antibacterianos/administração & dosagem , Antibacterianos/metabolismo , Feminino , Humanos , Masculino , Pivampicilina/farmacologia , Talampicilina/farmacologia
14.
Jpn J Antibiot ; 38(9): 2453-80, 1985 Sep.
Artigo em Japonês | MEDLINE | ID: mdl-3908737

RESUMO

A comparative double blind study of lenampicillin (LAPC, KBT-1585) and talampicillin (TAPC) was carried out in order to objectively evaluate efficacy, safety and utility of LAPC in treatment of 238 patients with oral infections. Cases accepted by the Central Committee for evaluation of efficacy and utility were 218, consisting of 101 of the LAPC group and 117 of the TAPC group; safety were 234, consisting of 110 of LAPC and 124 of TAPC. Clinical effectiveness as rated by attending doctor was 84.2% for the LAPC group and 82.9% for the TAPC group. The clinical utility rating was 82.2% in the LAPC group and 82.1% in the TAPC group, showing no significant difference between the 2 drugs. Adverse reactions were found in 6 cases (5.5%) in the LAPC group and 5 cases (4.0%) in the TAPC group, showing no significant difference between the 2 drugs. Cases accepted by the controllers for evaluation of efficacy and utility were 236, consisting of 111 cases of LAPC and 125 cases of TAPC. Those for safety were 236, consisting of 111 cases of LAPC and 125 of TAPC. The clinical effectiveness rating was 77.5% in the LAPC group and 79.2% in the TAPC group. Clinical utility rating was 75.7% in the LAPC group and 78.4% in the TAPC group. Rate of adverse reactions was 5.4% in the LAPC group and 4.0% in the TAPC group, showing no significant difference between the 2 drugs. Cases evaluated for efficacy according to numerical rating on the 3rd day were 200 cases, consisting of 93 of LAPC and 107 of TAPC. The effectiveness rate was 83.9% in the LAPC group and 95.3 in the TAPC group, showing a significant difference between the 2 drugs. On the other hand, taking into consideration evaluation scores of the 5th day, the effectiveness rate was 88.7% in the LAPC group and 96.1% in the TAPC group, showing no significant difference between the 2 drugs. The effectiveness rate in cases of isolated organisms was 84.9% in the LAPC group and 79.7% in the TAPC group, showing no significant difference between the 2 drugs. Adverse reactions were mostly of gastrointestinal origin. Symptoms were not serious and disappeared soon after administration was discontinued or immediately after administration was completed.(ABSTRACT TRUNCATED AT 400 WORDS)


Assuntos
Ampicilina/análogos & derivados , Infecções Bacterianas/tratamento farmacológico , Doenças da Boca/tratamento farmacológico , Talampicilina/uso terapêutico , Adolescente , Adulto , Idoso , Ampicilina/efeitos adversos , Ampicilina/farmacologia , Ampicilina/uso terapêutico , Bactérias Aeróbias/efeitos dos fármacos , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Bactérias Gram-Negativas/efeitos dos fármacos , Humanos , Doenças Maxilomandibulares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Resistência às Penicilinas , Periodontite/tratamento farmacológico , Talampicilina/efeitos adversos , Talampicilina/farmacologia
15.
Jpn J Antibiot ; 38(8): 2149-54, 1985 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-3852896

RESUMO

Forty-three cases were studied to determine the most optimal timing to discontinue an oral antibacterial agent for preventing urinary tract infection after transurethral prostatectomy. On the 5th postoperative day intravenous antibiotic treatment was replaced by oral medication of 1.5 g talampicillin hydrochloride (TAPC, Yamacillin), which was tapered and discontinued depending on the urinary findings. Nine out of 15 cases who discontinued the medication within 2 weeks failed to keep the urine sterile. It may be advisable to continue the medication at least 3 weeks and to discontinue thereafter when pyuria has vanished. All 24 cases who followed this principle became sterile within 8 weeks. Medication continued over 8 weeks seemed to have no additional benefit. Four cases dropped out from this treatment mainly because of gastrointestinal symptoms.


Assuntos
Ampicilina/análogos & derivados , Prostatectomia , Talampicilina/administração & dosagem , Administração Oral , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Resistência às Penicilinas , Cuidados Pós-Operatórios , Infecções Urinárias/prevenção & controle
16.
J Oral Maxillofac Surg ; 43(4): 270-6, 1985 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-3856643

RESUMO

Eighty-one patients who underwent the extraction of impacted mandibular third molars in the nonfasting state were given a single oral dose of talampicillin (500 mg) preoperatively. Specimens of venous blood (n = 132), gingiva (n = 70), mandibular bone (n = 78), dental follicle (n = 63), and dental pulp (n = 59) were obtained during the operation and assayed for ampicillin content. The mean peak concentrations in serum (9.64 micrograms/ml), gingiva (4.72 micrograms/mg), mandibular bone (1.77 micrograms/ml), dental follicle (3.46 micrograms/ml), and dental pulp (5.53 micrograms/mg) all occurred at approximately 150 minutes after administration of talampicillin. The ratios of the corresponding serum concentration to the peak concentrations in the various oral tissues when both were plotted as drug concentration curves were: gingiva, 0.50; mandibular bone, 0.16; dental follicle, 0.34; and dental pulp, 0.52. Talampicillin was absorbed well by the intestine, and sufficient concentrations of the resulting metabolite, ampicillin, were found in oral tissues.


Assuntos
Ampicilina/análogos & derivados , Ampicilina/análise , Polpa Dentária/análise , Saco Dentário/análise , Gengiva/análise , Mandíbula/análise , Talampicilina/administração & dosagem , Germe de Dente/análise , Administração Oral , Adolescente , Adulto , Idoso , Ampicilina/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dente Serotino/cirurgia , Fatores de Tempo , Dente Impactado/cirurgia
17.
Gen Pharmacol ; 16(3): 273-5, 1985.
Artigo em Inglês | MEDLINE | ID: mdl-4018542

RESUMO

The concentrations of ampicillin (ABPC) from talampicillin (TAPC) and cefadroxil (CDX) in serum and mixed saliva were assayed by the thin layer disc plate method. Talampicillin and cefadroxil (500 mg) were given by a single oral administration. The relationships between serum and mixed saliva ampicillin and cefadroxil concentrations were evaluated in the paired specimens collected from 10 different persons, respectively. The means of concentration ratios of mixed saliva to serum ampicillin and cefadroxil were 0.006 +/- 0.003 and 0.025 +/- 0.010 (mean +/- SD), respectively. Significant correlation coefficients between mixed saliva and serum concentrations were found for both ampicillin and cefadroxil, which were r = 0.78, P less than 0.001, and r = 0.67, P less than 0.001, respectively.


Assuntos
Ampicilina/análogos & derivados , Ampicilina/metabolismo , Cefadroxila/metabolismo , Saliva/metabolismo , Talampicilina/metabolismo , Adulto , Ampicilina/sangue , Cefadroxila/sangue , Humanos , Cinética , Masculino
19.
Br J Vener Dis ; 58(3): 180-1, 1982 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-7082979

RESUMO

Four hundred and sixty women with uncomplicated gonorrhea were treated with a single oral dose of 1.5 g talampicillin. The success rate among those who attended for at least one follow-up examination after treatment was 99.14%. The antibiotic was well tolerated and no side effects were reported. Talampicillin given under supervision has proved to be the most effective and safest treatment in this area. A smaller dosage of talampicillin than ampicillin is required, the drug is better tolerated by the patient, and the time of nursing staff is saved.


Assuntos
Ampicilina/análogos & derivados , Gonorreia/tratamento farmacológico , Talampicilina/uso terapêutico , Adulto , Feminino , Seguimentos , Humanos
20.
Chemotherapy ; 28(3): 218-23, 1982.
Artigo em Inglês | MEDLINE | ID: mdl-6980099

RESUMO

9 children presenting with an ampicillin-sensitive coliform urinary tract infection were treated with talampicillin using 1 week of full-dose treatment followed by low-dose prophylaxis. The bowel coliforms were ampicillin-resistant at the start in one girl and became resistant in the remaining 8 within 4 months. During a total of 44 months of talampicillin therapy, 6 girls (2 with vesico-ureteric reflux) developed a symptomatic re-infection of the urinary tract, a recurrence rate of 1 per 7.3 months, or 1.6 recurrences per annum. A further 12 girls were given prophylactic talampicillin, 9 after an initial therapeutic course of co-trimoxazole for 1 week and 3 following a period of prophylaxis with low-dose co-trimoxazole. The rectal swab from one girl showed partial ampicillin resistance but 9 of the remaining 11 showed that a predominance of ampicillin-resistance coliforms had emerged in the bowel flora within 4 months. 5 of the 12 also developed a symptomatic ampicillin-resistant urinary infection within 4 months, a recurrence rate of 1 per 7.1 months or 1.7 recurrences per annum. Talampicillin, though very effective in treating urinary infection, is not recommended for the prevention of subsequent recurrence.


Assuntos
Ampicilina/análogos & derivados , Talampicilina/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Criança , Pré-Escolar , Combinação de Medicamentos/uso terapêutico , Feminino , Humanos , Lactente , Masculino , Recidiva , Sulfametoxazol/uso terapêutico , Trimetoprima/uso terapêutico , Combinação Trimetoprima e Sulfametoxazol , Infecções Urinárias/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...